News

Panel recommends statins for adults with HIV at risk for cardiovascular disease
In February 2024, the U.S. Department of Health and Human Services Panel for the Use of Antiretroviral Agents in Adults and ...
TMCnet4d
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%. Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advan ...
Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good
Discover why Dynavax Technologies' stock dropped 25% despite HEPLISAV-B's growth & double-digit projections through 2030.
The Lancet6d
A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles
The Coalition for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, ...